ANGLE plc (GB:AGL) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
ANGLE plc, a trailblazer in liquid biopsy technology, has announced a new collaboration with Recursion Pharmaceuticals to conduct a pilot study using ANGLE’s Parsortix CTC analysis system. This partnership represents ANGLE’s fourth major contract in 2024, cementing its growth in the large pharma services sector. The study’s success could lead to larger contracts, underscoring the potential impact of ANGLE’s innovative solutions in clinical oncology and drug development.
For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue